posted on 2022-09-09, 10:23authored byAgnethe Eltoft, Tom Wilsgaard, Melinda B Roaldsen, Mary-Helen Soyland, Erik Lundstrom, Jesper Petersson, Bent Indredavik, Jukka Putaala, Hanne Christensen, Janika Korv, Dalius Jatuzis, Stefan T Engelter, Gian Marco De Marchis, David J Werring, Thompson Robinson, Arnstein Tveiten, Ellisiv B Mathiesen
Background: Patients with wake-up ischemic stroke are frequently excluded from thrombolytic treatment due to unknown symptom onset time and limited availability of advanced imaging modalities. The Tenecteplase in Wake-up Ischaemic Stroke Trial (TWIST) is a randomized controlled trial of intravenous tenecteplase 0.25 mg/kg and standard care versus standard care alone (no thrombolysis) in patients who wake up with acute ischemic stroke and can be treated within 4.5 h of wakening based on non-contrast CT findings. Objective: To publish the detailed statistical analysis plan for TWIST prior to unblinding. Methods: The TWIST statistical analysis plan is consistent with the Consolidating Standard of Reporting Trials (CONSORT) statement and provides clear and open reporting. Discussion: Publication of the statistical analysis plan serves to reduce potential trial reporting bias and clearly outlines the pre-specified analyses. Trial registration: ClinicalTrials.govNCT03181360. EudraCT Number 2014-000096-80. WHO ICRTP registry number ISRCTN10601890.
History
Author affiliation
College of Life Sciences and NIHR Biomedical Research Centre, University of Leicester